ReMYND was founded in 2002 as a spin-off of the KU Leuven. The company started as a CRO, offering pre-clinical pharmacology services to large pharmaceutical clients worldwide with a focus on central nervous system (CNS, e.g. Alzheimer’s, Parkinson’s) diseases. After a number of years, it started developing their own pipeline of drug candidates for protein misfolding disorders around their phenotypic screening model (cf. infra), thereby leveraging the experience they built up in the service division.